Madersbacher H, Knoll M
Neuro-Urology Unit, University Hospital, Innsbruck, Austria.
Eur Urol. 1995;28(4):340-4. doi: 10.1159/000475078.
Topical oxybutynine (Oxy) has been used successfully in neurogenic bladder patients who remained wet on oral anticholinergics or could not tolerate oral medication. However, little is known about the pharmacokinetics of intravesical Oxy. The aim of this study was to evaluate the resorption rate of intravesically given Oxy in the bladder in comparison with oral intake, and to find out which pharmacological properties of the drug are responsible for its effect when given intravesically. Our results indicate that peak plasma levels of intravesical Oxy appear later, are lower and stay longer compared to oral intake. Cystometries before, 20 min and 2 h after intravesical application of Oxy indicate that the main effect of intravesical Oxy on the detrusor is systemic due to its resorption. Our findings confirm the clinical experience that intravesical Oxy is well tolerated, very efficacious and better than oral medication.
局部用奥昔布宁（Oxy）已成功用于口服抗胆碱能药物后仍有尿失禁或无法耐受口服药物的神经源性膀胱患者。然而，关于膀胱内奥昔布宁的药代动力学知之甚少。本研究的目的是评估膀胱内给予奥昔布宁与口服给药相比在膀胱中的吸收速率，并找出该药物膀胱内给药时产生作用的药理特性。我们的结果表明，与口服给药相比，膀胱内奥昔布宁的血浆峰值水平出现较晚、较低且持续时间更长。膀胱内应用奥昔布宁前、应用后20分钟和2小时的膀胱测压表明，膀胱内奥昔布宁对逼尿肌的主要作用是由于其吸收导致的全身性作用。我们的研究结果证实了临床经验，即膀胱内奥昔布宁耐受性良好、非常有效且优于口服药物。
